Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>In our 2/25/25 Compass, we discussed our expectation for near-term downside. Also said one or two 8-10% pullbacks in a given year on the SPX is common</li>
<li>And said to not be surprised if there is a test of the bottom of the range at either 5770-5850 or 5600-5670, where we would be buyers</li>
<li>The SPX had a -10.3% peak-to-trough decline, with support showing up at 5500; close enough to our 10% pullback and 5600 level. This has been a stellar buy area</li>
</ul>


In our 2/25/25 Compass, we discussed our expectation for near-term downside. Also said one or two 8-10% pullbacks in a given year on the SPX is common
And said to not be surprised if there is a test of the bottom of the range at either 5770-5850 or 5600-5670, where we would be buyers
The SPX had a -10.3% peak-to-trough decline, with support showing up at 5500; close enough to our 10% pullback and 5600 level. This has been a stellar buy area


Major Low Likely in Place on S&P 500; Bullish Outlook Intact if Above 5500-5600

Private Markets, Angel and Secondary Investing, Sacra

Sacra

Private Markets, Angel and Secondary Investing

Bringing transparency to private markets so investors, founders, and employees can build on conviction. Sacra delivers deeply researched insights on the private companies shaping tomorrow's markets. By surfacing the data, context, and operator perspective that are missing from private markets today, we help secondary buyers and sellers price equity accurately and unlock liquidity for the people building these businesses.

Private Capital Markets

<ul><li>As of June 2026, Lila is in talks to raise approximately $2 billion in a Series B at a pre-money valuation of roughly $8.5 billion, implying a post-money valuation of approximately $10.5 billion.</li><li>By the time of its Series A in October 2025, Lila's first AISF had already closed the loop across hundreds of thousands of AI-driven experiments.</li><li>The planned 200,000-square-foot Cambridge AISF, targeted for Q3 2026 opening, is the clearest near-term capacity lever.</li></ul>

As of June 2026, Lila is in talks to raise approximately $2 billion in a Series B at a pre-money valuation of roughly $8.5 billion, implying a post-money valuation of approximately $10.5 billion.By the time of its Series A in October 2025, Lila's first AISF had already closed the loop across hundreds of thousands of AI-driven experiments.The planned 200,000-square-foot Cambridge AISF, targeted for Q3 2026 opening, is the clearest near-term capacity lever.

<ul><li>Sacra estimates BillionToOne hit $153M in revenue in 2024, more than doubling from $72M in 2023, representing 112% year-over-year growth.</li><li>The company generates revenue primarily through its prenatal testing business, which has captured 15% market share in the US and is profitable.</li><li>BillionToOne reached a valuation of over $1 billion following a $130 million Series D financing round.</li></ul>

Sacra estimates BillionToOne hit $153M in revenue in 2024, more than doubling from $72M in 2023, representing 112% year-over-year growth.The company generates revenue primarily through its prenatal testing business, which has captured 15% market share in the US and is profitable.BillionToOne reached a valuation of over $1 billion following a $130 million Series D financing round.

<ul><li>We estimate Apeel’s 2021 revenue at $22M, up 21% from 2020.</li><li>It was last valued at $2B at an estimated 100x valuation/revenue multiple.</li><li>Apeel recently acquired spectral imaging startup ImpactVision, which lets growers see inside their produce to understand its ripening window.</li></ul>

We estimate Apeel’s 2021 revenue at $22M, up 21% from 2020.It was last valued at $2B at an estimated 100x valuation/revenue multiple.Apeel recently acquired spectral imaging startup ImpactVision, which lets growers see inside their produce to understand its ripening window.

Strand Therapeutics / Private Capital Markets

<ul><li>Strand Therapeutics raised $153 million in a Series B round led by Kinnevik in August 2025, bringing the company's valuation to approximately $550 million.</li><li>The lead product, STX-001, is administered via direct injection into tumors and encodes mRNA instructions for producing interleukin-12 (IL-12), an immune-stimulating protein.</li><li>Phase 1 data from 22 checkpoint-refractory cancer patients reported one complete response and multiple partial responses, with no dose-limiting toxicities observed.</li></ul>

Strand Therapeutics raised $153 million in a Series B round led by Kinnevik in August 2025, bringing the company's valuation to approximately $550 million.The lead product, STX-001, is administered via direct injection into tumors and encodes mRNA instructions for producing interleukin-12 (IL-12), an immune-stimulating protein.Phase 1 data from 22 checkpoint-refractory cancer patients reported one complete response and multiple partial responses, with no dose-limiting toxicities observed.

Primer: Strand Therapeutics - 07 Dec 2025

United States

Tempus AI, Inc. operates as a clinical laboratory. The Company provides genomic sequencing services and analyze molecular and therapeutic data to help physicians to make real-time and data-driven decisions.Tempus AI serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Tempus AI (TEM US)

Major Low Likely in Place on S&P 500; Bullish Outlook Intact if Above 5500-5600

Major Low Likely in Place on $SPX; Bullish Outlook Intact if Above 5500-5600. 5670-5718 is short-term gap support; Power in hands of bulls if...

Vermilion Research

Primer: Lila Sciences - 04 Jun 2026

Autonomous lab system for AI-driven hypothesis generation, experiment design, and execution

Sacra

Primer: BillionToOne - 18 May 2026

Genetic testing tool for prenatal screening and cancer therapy selection via blood samples

Sacra

Primer: Apeel - 09 Mar 2026

Plant-based coating that extends shelf life of produce for retailers and suppliers

Sacra

Primer: Strand Therapeutics - 07 Dec 2025

mRNA therapy developer using genetic circuits for targeted cancer and immune system activation

Sacra

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)